In today’s briefing:
- Wuxi XDC Placement – A Repeat of Biologics Placement Saga, Last Deal Did Well
- HCA Healthcare: The Volume Growth & Payer Mix Dynamics! – Major Drivers
- Hisamitsu Pharmaceutical (4530 JP): Growth Momentum Intact; FY25 Guidance Raised
- Hardman & Co Monthly: January 2025
Wuxi XDC Placement – A Repeat of Biologics Placement Saga, Last Deal Did Well
- WuXi AppTec (2359 HK) aims to raise around US$150m via selling around 3% stake in WuXi XDC Cayman (2268 HK).
- WuXi XDC Cayman (WXDC) is a contract research, development, and manufacturing organization (CRDMO) focused on the global antibody drug conjugates (ADC) and broader bioconjugate market providing integrated and end-to-end services.
- In this note, we will talk about the placement and run the deal through our ECM framework.
HCA Healthcare: The Volume Growth & Payer Mix Dynamics! – Major Drivers
- HCA Healthcare recently held its third-quarter earnings call, and the insights provided offer a complex view of the company’s current position and future outlook.
- The financial results reflected strong performance despite notable challenges, particularly from recent hurricanes.
- Positively, HCA Healthcare reported substantial year-over-year growth in several key financial metrics.
Hisamitsu Pharmaceutical (4530 JP): Growth Momentum Intact; FY25 Guidance Raised
- Hisamitsu Pharmaceutical Co (4530 JP) reported single-digit revenue growth and net profit growth in low-teens during 9MFY25, on the back of 13% YoY growth in Salonpas focused OTC segment.
- Rx business revenue grew 4% YoY as new products such as Zicthoru, Apohide, Combipatch, Vivelle-Dot etc clocked healthy numbers.
- Hisamitsu raised its FY25 guidance for revenue by 1% to ¥154B, operating profit by 24% to ¥18B, and net profit by 24% to ¥20.5B.
Hardman & Co Monthly: January 2025
- Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.
- Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.
- Despite this, some companies can still make extremely attractive returns for investors.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
